hepatology India

AstraZeneca’s Imfinzi‑based combo slows liver cancer progression in late‑stage trial

London‑based pharma major AstraZeneca has reported that its liver‑cancer therapy combination, built around its immunotherapy Imfinzi (durvalumab), significantly slowed disease progression…